대한한의학방제학회지 (Herbal Formula Science)

  • 제30권3호
  • /
  • Pages.175-182
  • /
  • 2022
  • /
  • 1229-1218(pISSN)
  • /
  • 2288-5641(eISSN)
대한한의학방제학회 (The Korean Medicine Society for the Herbal Formula Study)
권호 표지
DOI QR코드

DOI QR Code

암치료를 위한 네트워크 기반 접근방식 활용 시스템 수준 연구

Investigating herbal active ingredients and systems-level mechanisms on the human cancers

  • 이원융 (가천대학교 한의과대학)
  • 투고 : 2022.08.21
  • 심사 : 2022.08.26
  • 발행 : 2022.08.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective : This study aims to investigate the active ingredients and potential mechanisms of the beneficial herb on human cancers such as the liver by employing network pharmacology. Methods : Ingredients and their target information was obtained from various databases such as TM-MC, TTD, and Drugbank. Related protein for liver cancer was retrieved from the Comparative Toxicogenomics Database and literature. A hypergeometric test and gene set enrichment analysis were conducted to evaluate associations between protein targets of red ginseng (Panax ginseng C. A. Meyer) and liver cancer-related proteins and identify related signaling pathways, respectively. Network proximity was employed to identify active ingredients of red ginseng on liver cancer. Results : A compound-target network of red ginseng was constructed, which consisted of 363 edges between 53 ingredients and 121 protein targets. MAPK signaling pathway, PI3K-Akt signaling pathway, p53 signaling pathway, TGF-beta signaling pathway, and cell cycle pathway was significantly associated with protein targets of red ginseng. Network proximity results indicated that Ginsenoside Rg1, Acetic Acid, Ginsenoside Rh2, 20(R)-Ginsenoside Rg3, Notoginsenoside R1, Ginsenoside Rk1, 2-Methylfuran, Hexanal, Ginsenoside Rd, Ginsenoside Rh1 could be active ingredients of red ginseng against liver cancer. Conclusion : This study suggests that network-based approaches could be useful to explore potential mechanisms and active ingredients of red ginseng for liver cancer.

키워드

과제정보

이 성과는 정부(과학기술정보통신부)의 재원으로 한국연구재단의 지원을 받아 수행된 연구임 (NRF-2022R1I1A1A01057053).

참고문헌

  1. Shirakami Y, Sakai H, Shimizu M. Retinoid roles in blocking hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2015;4(4):1-7.
  2. Mancuso A, Perricone G. Hepatocellular carcinoma and liver transplantation: state of the art. J Clin Transl Hepatol. 2014;2(3):176-181.
  3. Nam KY, Lee NR, Moon BD, Song GY, Shin HS, Choi JE. Changes of ginsenosides and color from black ginsengs prepared by steaming-drying cycles. Korean J Med Crop Sci. 2012;20(1):27-35. https://doi.org/10.7783/KJMCS.2012.20.1.027
  4. Oh J, Jeon S Bin, Lee Y, Lee H, Kim J, Kwon BR, et al. Fermented red ginseng extract inhibits cancer cell proliferation and viability. J Med Food. 2015;18(4):421-428. https://doi.org/10.1089/jmf.2014.3248
  5. Zhu GY, Li YW, Tse AKW, Hau DKP, Leung CH, Yu ZL, et al. 20 (S)-Protopanaxadiol, a metabolite of ginsenosides, induced cell apoptosis through endoplasmic reticulum stress in human hepatocarcinoma HepG2 cells. Eur J Pharmacol. 2011;668(1):88-98. https://doi.org/10.1016/j.ejphar.2011.06.008
  6. Tian S, Huang P, Gu Y, Yang J, Wu R, Zhao J, et al. Systems Biology Analysis of the Effect and Mechanism of Qi-Jing-Sheng-Bai Granule on Leucopenia in Mice. 2019;10:1-16.
  7. Hopkins AL. Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-90. https://doi.org/10.1038/nchembio.118
  8. Lee WY, Lee CY, Kim YS, Kim CE. The methodological trends of traditional herbal medicine employing network pharmacology. Biomolecules. 2019;9(8):1-15.
  9. Guney E, Menche J, Vidal M, Barabasi AL. Network-based in silico drug efficacy screening. Nat Commun. 2016;7:1-13.
  10. Lee WY, Lee CY, Lee JS, Kim CE. Identifying candidate flavonoids for non-alcoholic fatty liver disease by network-based strategy. Front Pharmacol. 2022;13(892559):1-14.
  11. Kim SK, Nam SJ, Jang H, Kim A, Lee JJ. TM-MC: A database of medicinal materials and chemical compounds in Northeast Asian traditional medicine. BMC Complement Altern Med. 2015;15(218):1-8. https://doi.org/10.1186/s12906-015-0520-z
  12. Huang Y, Fang J, Lu W, Wang Z, Wang Q, Hou Y, et al. A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling. Cell Chem Biol. 2019;26:1143-1158.e6. https://doi.org/10.1016/j.chembiol.2019.05.004
  13. Szklarczyk D, Santos A, Von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: Augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2016;44:D380-D384. https://doi.org/10.1093/nar/gkv1277
  14. Zhu F, Han BC, Kumar P, Liu XH, Ma XH, Wei XN, et al. Update of TTD: Therapeutic Target Database. Nucleic Acids Res. 2009;38:D787-791.
  15. Koopmans F, van Nierop P, Andres-Alonso M, Byrnes A, Cijsouw T, Coba MP, et al. SynGO: an evidence-based, expert-curated knowledge base for the synapse. Neuron. 2019;103(2):217-234. https://doi.org/10.1016/j.neuron.2019.05.002
  16. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-2504. https://doi.org/10.1101/gr.1239303
  17. Davis AP, Grondin CJ, Johnson RJ, Sciaky D, McMorran R, Wiegers J, et al. The Comparative Toxicogenomics Database: Update 2019. Nucleic Acids Res. 2019;47:D948-D954 https://doi.org/10.1093/nar/gky868
  18. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550. https://doi.org/10.1073/pnas.0506580102
  19. Gene Ontology Consortium. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2004;32:D258-D261 https://doi.org/10.1093/nar/gkh036
  20. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999;27(1):29-34. https://doi.org/10.1093/nar/27.1.29
  21. Gao Y, Chu S, Zhang Z, Chen N. Hepataprotective effects of ginsenoside Rg1-A review. J Ethnopharmacol. 2017;206:178-183. https://doi.org/10.1016/j.jep.2017.04.012
  22. Yang Z, Zhao T, Liu H, Zhang L. Ginsenoside Rh2 inhibits hepatocellular carcinoma through β-catenin and autophagy. Sci Rep.2016;6(19383):1-13. https://doi.org/10.1038/s41598-016-0001-8
  23. Li Y, Li Z, Jia Y, Ding B, Yu J. In vitro anti-hepatoma activities of notoginsenoside R1 through downregulation of tumor promoter miR-21. Digestive diseases and sciences, 2020;65(5):1364-1375. https://doi.org/10.1007/s10620-019-05856-4
  24. Kim YJ, Kwon HC, Ko H, Park JH, Kim HY, Yoo JH, Yang HO. Anti-tumor activity of the ginsenoside Rk1 in human hepatocellular carcinoma cells through inhibition of telomerase activity and induction of apoptosis. Biological and Pharmaceutical Bulletin, 2008;31(5):826-830. https://doi.org/10.1248/bpb.31.826